The Biomedical Advanced Research and Development Authority (BARDA) has issued a Request for Proposals (RFP) for anthrax antitoxin products to treat individuals with symptomatic anthrax disease resulting from aerosol release of Bacillus anthracis spores.
The solicitation calls for manufacture and delivery to the Strategic National Stockpile anthrax antitoxin suitable for use in humans in a declared emergency or as an FDA-approved product.
Further requirements of the contract include development and maintenance of master cell banks for the production of monoclonal antibody anthrax antitoxins, and collection and storage of human immune plasma for the manufacture of polyclonal anthrax antitoxins.
The RFP supports the Department of Health and Human Services (HHS) plan for acquisition and storage of medical countermeasures that will mitigate injuries caused by exposure to chemical, biological threat agents, physical radiologic and nuclear exposures.
The government contemplates multiple awards of Indefinite Delivery Indefinite Quantity (IDIQ) contracts. The anticipated period of performance will be for base period of up to five years or 60 months.
Full details are available under Solicitation Number: RFP-12-100-SOL-00026. The deadline to submit proposals is July 30, 2012.
